Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Regulation of the Inflammasome by Gasdermin D mRNA Chimerism

Award Number: F31AI181475
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 01/01/2025
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

Regulation of the Inflammasome by Gasdermin D mRNA Chimerism - ABSTRACT Appreciation for the complexity of RNA processing is essential for understanding regulatory mechanisms of innate immunity. We uncovered novel splice variants that occur through the fusion of two distinct RNA transcripts (chimeric mRNA) in murine macrophages, including a fusion transcript containing Gsdmd and Tmem106a (Gsdmd:Tmem106a), two genes situated on separate chromosomes. Following inflammasome assembly, triggered by microbial signals and cellular damage, gasdermin D (GSDMD) is cleaved into its active form by inflammatory caspases. GSDMD N-terminal (GSDMD-NT) fragments oligomerize and create pores in the plasma membrane allowing for the release of IL-1β. This often triggers inflammatory cell death but occasionally allows for longer lasting states of pro-inflammatory cytokine release. GSDMD is essential for host defense against a variety of bacterial pathogens but excessive inflammasome activation and GSDMD pore formation is linked to autoinflammatory diseases, sepsis, and cytokine release syndrome. Regulatory mechanisms of pore formation, acting downstream of GSDMD cleavage, are a topic of intensive investigation. To functionally assess the role of Gsdmd:Tmem106a downstream of inflammasome activation, we selectively knocked-down this chimeric mRNA using RNA interference and discovered that it is required for optimal IL-1β release. Based on our preliminary results, this proposal will test the hypothesis that Gsdmd:Tmem106a facilitates GSDMD pore formation and contributes to physiological inflammation. To robustly investigate the function of this chimeric mRNA and protein, we generated two mouse models: endogenous GSDMD:TMEM106A protein tag mice (GTMyc) and GSDMD:TMEM106A-deficient mice (GTstop). Aim 1 of this proposal will mechanistically interrogate Gsdmd:Tmem106a function by first characterizing chimeric protein localization and interacting partners during inflammasome activation using GTMyc mice (Aim 1.1) and secondly, by assessing GSDMD-NT oligomerization and pore formation in GTstop bone marrow derived macrophages, as well as by using in vitro systems of GSDMD- NT pore formation that function independently of the upstream inflammasome (Aim 1.2). As Gsdmd:Tmem106a encodes a novel protein with a truncated GSDMD-NT, we hypothesize that it promotes native GSDMD pore formation through direct interaction. Aim 2 of this proposal will evaluate the in vivo expression landscape of Gsdmd:Tmem106a following systemic LPS exposure (Aim 2.1), as well as use GTstop mice to assess its physiological role in LPS sepsis induced inflammation and death (Aim 2.2). We hypothesize that Gsdmd:Tmem106a will be robustly expressed following LPS treatment, and that this chimeric mRNA plays a role in exacerbating inflammation and LPS sepsis lethality, as native GSDMD has been reported to. Taken together, this work will uncover a novel mechanism of GSDMD pore formation, and demonstrate that chimeric mRNA are present and functional during inflammation, highlighting an entirely new class of mRNA for further exploration in the immune system.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $38,058 )
2026	2026	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	25 SHATTUCK ST	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	2	12/24/2025	NON-COMPETING CONTINUATION	$37,482
2026	2026	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	25 SHATTUCK ST	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	2	4/2/2026	NON-COMPETING CONTINUATION	$576
														Subtotal = $38,058

Issue Date FY: 2025 ( Subtotal = $43,767 )
2025	2025	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	25 SHATTUCK ST	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	11/19/2024	NEW	$43,203
2025	2025	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	25 SHATTUCK ST	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	1	11/19/2024	NEW	$0
2025	2025	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	25 SHATTUCK ST	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	002	1	7/29/2025	NEW	$564
														Subtotal = $43,767

Grand Total All Awards = $81,825

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Regulation of the Inflammasome by Gasdermin D mRNA Chimerism

Award Number: F31AI181475

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 01/01/2025

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer